Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery

Molecular Pain

Volumn 10, Issue 1, 2014, Pages

  Rahn, Elizabeth J ^a,d   Deng, Liting ^b   Thakur, Ganesh A ^c   Vemuri, Kiran ^c   Zvonok, Alexander M ^c   Lai, Yvonne Y ^b   Makriyannis, Alexandros ^c   Hohmann, Andrea G ^a,b  

^a University of Georgia   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Cannabinoid; CB1; CB2; Chemotherapy; Cold allodynia; Mechanical allodynia; Osmotic mini pump; Paclitaxel

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1',1' DIMETHYLHEPTYL) 1 HYDROXY 9 METHOXY 6H BENZO[C]CHROMENE 6 ONE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AM 1710; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; PACLITAXEL; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; COLD SENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; LOCOMOTION; LUMBAR SPINE; MALE; MECHANICAL STIMULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION;

ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CANNABINOIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPERALGESIA; MALE; MOTOR ACTIVITY; NEURALGIA; PACLITAXEL; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 84899478892     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-10-27     Document Type: Article

References (49)

1. LaBuda CJ, Koblish M, Little PJ. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 2005, 527:172-174. 10.1016/j.ejphar.2005.10.020, 16316653.
2. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75:111-119. 10.1016/S0304-3959(97)00213-3, 9539680.
3. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006, 18:949-956. 10.1111/j.1365-2982.2006.00819.x, 16961698.
4. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009, 6:713-737. 10.1016/j.nurt.2009.08.002, 2755639, 19789075.
5. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515. 10.1016/j.ejca.2008.04.018, 18571399.
6. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007, 20:719-725.
7. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15:3081-3094. 10.2174/092986708786848569, 19075655.
8. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009, 10:1146-1150. 10.1016/j.jpain.2009.04.006, 2783933, 19595634.
9. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980, 77:1561-1565. 10.1073/pnas.77.3.1561, 348536, 6103535.
10. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006, 72:151-169.
11. Burgos E, Gomez-Nicola D, Pascual D, Martin MI, Nieto-Sampedro M, Goicoechea C. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 2012, 682:62-72. 10.1016/j.ejphar.2012.02.008, 22374260.
12. Zhang H, Yoon SY, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain 2012, 13:293-303. 10.1016/j.jpain.2011.12.002, 3294066, 22285612.
13. Pascual D, Goicoechea C, Suardiaz M, Martin MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005, 118:23-34. 10.1016/j.pain.2005.07.008, 16213089.
14. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008, 327:584-591. 10.1124/jpet.108.141994, 2682949, 18664590.
15. Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, Hohmann AG. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 2012, 8:71. 10.1186/1744-8069-8-71, 3502129, 22998838.
16. Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, Hu J, Craig S, Hittelman WN. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anaesth Analg 2012, 114:1104-1120.
17. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007, 152:765-777. 2190028, 17572696.
18. Rahn EJ, Thakur GA, Vemuri VK, Makriyannis A, Hohmann AG. Prophylactic treatment with cannabinoids suppresses the development of neuropathic nociception resulting from treatment with the chemotherapeutic agent paclitaxel in rats [abstract]. Soc Neurosci Abstr 2010, SS12:681.3.
19. Guindon J, Desroches J, Dani M, Beaulieu P. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharm 2007, 568:173-176.
20. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142. 10.1016/j.pain.2004.01.021, 15082135.
21. Zhao C, Chen L, Tao YX, Tall JM, Borzan J, Ringkamp M, Meyer RA, Raja SN. Lumbar sympathectomy attenuates cold allodynia but not mechanical allodynia and hyperalgesia in rats with spared nerve injury. J Pain 2007, 8:931-937. 10.1016/j.jpain.2007.06.008, 17693138.
22. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009, 330:902-910. 10.1124/jpet.109.155465, 2729802, 19502530.
23. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000, 87:149-158. 10.1016/S0304-3959(00)00276-1, 10924808.
24. Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 2013, 8:e80440. 10.1371/journal.pone.0080440, 3840025, 24282543.
25. Svizenska IH, Brazda V, Klusakova I, Dubovy P. Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model. J Histochem Cytochem 2013, 61:529-547. 10.1369/0022155413491269, 23657829.
26. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 2006, 83:1310-1322. 10.1002/jnr.20821, 16511871.
27. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006, 126:102-114. 10.1016/j.pain.2006.06.016, 1776167, 16844297.
28. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001, 94:293-304. 10.1016/S0304-3959(01)00363-3, 11731066.
29. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001, 133:586-594. 10.1038/sj.bjp.0704110, 1572814, 11399676.
30. Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav 2011, 98:493-502. 10.1016/j.pbb.2011.02.024, 3089437, 21382397.
31. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, Brown DL. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 2008, 155:1104-1116. 2597252, 18846037.
32. Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anaesth Analg 2010, 111:99-109.
33. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589. 10.1038/nn1457, 15856067.
34. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martin MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007, 81:468-479. 10.1016/j.lfs.2007.06.012, 17673260.
35. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96:5780-5785. 10.1073/pnas.96.10.5780, 21937, 10318961.
36. Ji RR, Berta T, Nedergaard M. Glia and pain: Is chronic pain a gliopathy?. Pain 2013, 154:S10-28.
37. Zheng FY, Xiao WH, Bennett GJ. The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuries. Neuroscience 2011, 176:447-454. 3040270, 21195745.
38. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598. 10.1016/S0959-8049(01)00171-X, 11527683.
39. Spigelman I. Therapeutic Targeting of Peripheral Cannabinoid Receptors in Inflammatory and Neuropathic Pain States. Translational Pain Research: From Mouse to Man 2010, Boca Raton, FL: Frontiers in Neuroscience, Kruger L, Light AR.
40. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014, 47:166-173. 10.1016/j.jpainsymman.2013.02.018, 23742737.
41. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6:620-629. 10.1016/j.nurt.2009.07.003, 19789067.
42. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004, 109:150-161. 10.1016/j.pain.2004.01.029, 15082137.
43. Vajda EG, Lopez FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quin olin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther 2009, 328:663-670. 10.1124/jpet.108.146811, 19017848.
44. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000, 279:L895-L902.
45. Hoglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 2003, 84:491-502. 10.1046/j.1471-4159.2003.01533.x, 12558969.
46. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88. 10.1016/0304-3959(88)90026-7, 3340425.
47. Malan TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93:239-245. 10.1016/S0304-3959(01)00321-9, 11514083.
48. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994, 59:369-376. 10.1016/0304-3959(94)90023-X, 7708411.
49. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 2013, 67:94-109. 10.1016/j.phrs.2012.10.013, 3525790, 23127915.